Retatrutide's novel triple-agonist approach produced 28.7% weight loss in Phase 3 TRIUMPH-4 (confirming 24.2% in Phase 2) by adding glucagon and GIP receptor activation
American Society for Clinical Pharmacology and Therapeutics
Improvements in drug administration, including implantable devices, extended-release formulations, or non-invasive methods (like transdermal patches), may enhance patient satisfaction and broaden market appeal Impacted by recent drug approvals (for diverse applications) and substantial R&D investments from companies (to enhance delivery systems for GLP-1 drugs), the market is projected to witness steady growth in the coming decade
This hormone helps regulate your blood sugar after meals and reduces your appetite
What made the session even more compelling was its interdisciplinary perspective, bringing together insights from industry leaders, physicians, RDs, and AI-generated consumer modeling